Journal publications

Export 74 results:
[ Author(Desc)] Title Type Year
Filters: Type is Journal Article  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Antiretroviral Therapy Cohort Collaboration(ART-CC), Canadian Observational Cohort Collaboration(CANOC), UK Collaborative HIV Cohort Study(UK CHIC), Collaboration of Observational HIV Epidemiological Research in Europe(COHERE).  2016.  Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis. AIDS. 30(3)
Assoumou L., Brun-Vezinet F., Cozzi-Lepri A, Kuritzkes D., Phillips AN, Zolopa A., Degruttola V., Miller V., Costagliola D..  2008.  Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response. J Infect Dis. 198:470-80.
B
Bansi L, Geretti AM, Dunn DT, Hill T, Green H, Fearnhill E, Gazzard B, Nelson M, Porter K, Phillips AN et al..  2010.  Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART). J Acquir Immune Defic Syndr. 53:633-9.
Bansi L, Smith C, Phillips AN, Kirk S., Geretti AM, Johnson M, Mackie N, Post FA, Gazzard B, Dunn DT et al..  2011.  The impact of HIV drug resistance testing on changes to treatment. AIDS. 25:603-10.
Barber TJ, Harrison LJ, Asboe D, Williams I, Kirk S., Gilson R, Bansi L, Pillay D, Dunn DT.  2012.  Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. J Antimicrob Chemother. 67:995-1000.
Bulteel N, Bansi-Matharu L., Churchill D, Dunn DT, Bibby D., Hill T, Sabin CA, Nelson M.  2014.  The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort. J Infect. 68:77-84.
C
Cane P A, Chrystie I, Dunn DT, Evans B., Geretti AM, Green H, Phillips AN, Pillay D, Porter K, Pozniak A et al..  2005.  Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ. 331:1368.
Cane P A, Green H, Fearnhill E, Dunn DT.  2007.  Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptase. AIDS. 21:447-55.
Castro H, Pillay D, Cane P A, Asboe D, Cambiano V, Phillips AN, Dunn DT.  2013.  Persistence of HIV-1 transmitted drug resistance mutations. J Infect Dis. 208:1459-63.
Castro H, Pillay D, Sabin CA, Dunn DT.  2012.  Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance. BMC Med Res Methodol. 12:30.
Chakraborty R., Smith CJ, Dunn DT, Green H, Duong T., Doerholt K., Riordan A., Lyall H., Tookey P, Butler K. et al..  2008.  HIV-1 drug resistance in HIV-1-infected children in the United Kingdom from 1998 to 2004. Pediatr Infect Dis J. 27:457-9.
Chilton DN, Castro H, Lattimore S, Harrison LJ, Fearnhill E, Delpech V, Rice B., Pillay D, Dunn DT.  2010.  HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom. Antivir Ther. 15:985-91.
Collins IJ, Foster C, Tostevin A, Tookey P, Riordan A., Dunn DT, Gibb DM, Judd A.  2017.  Clinical Status of Adolescents with Perinatal HIV at Transfer to Adult Care in the UK/Ireland. Clin Infect Dis. Epub ahead of print
Cozzi-Lepri A.  2008.  Initiatives for developing and comparing genotype interpretation systems: external validation of existing rule-based interpretation systems for abacavir against virological response. HIV Med. 9:27-40.
Cozzi-Lepri A, Prosperi M.C, Kjaer J., Dunn DT, Paredes R, Sabin CA, Lundgren J, Phillips AN, Pillay D.  2011.  Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score PLoS One. 6:e25665.
D
De Luca A., Dunn DT, Zazzi M, Camacho R., Torti C., Fanti I., Kaiser R., Sonnerborg A., Codoner F.M, Van Laethem K. et al..  2013.  Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. J Infect Dis. 207:1216-20.
De Luca A., Flandre P., Dunn DT, Zazzi M, Wensing A., Santoro MM, Günthard HF, Wittkop L., Kordossis T., Garcia F. et al..  2016.  Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. J Antimicrob Chemother. 71:1352-60.
de Oliveira T, Pillay D, Gifford RJM.  2010.  The HIV-1 subtype C epidemic in South America is linked to the United Kingdom. PLoS One. 5:e9311.
Dolling D, Phillips AN, Delpech V, Pillay D, Cane P A, Crook A.M, Shepherd J., Fearnhill E, Hill T, Dunn DT.  2012.  Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men. HIV Med. 13:309-14.
Dolling D, Sabin CA, Delpech V, Smit E, Pozniak A, Asboe D, Leigh Brown A, Churchill D, Williams I, Geretti AM et al..  2012.  Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. BMJ. 345:e5253.